Canada - English - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 40mg - atorvastatin (atorvastatin calcium) 40mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 80mg - atorvastatin (atorvastatin calcium) 80mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 10mg - atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 20mg - atorvastatin (atorvastatin calcium) 20mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 40mg - atorvastatin (atorvastatin calcium) 40mg - hmg-coa reductase inhibitors

Canada - English - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 80mg - atorvastatin (atorvastatin calcium) 80mg - hmg-coa reductase inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - ezetimibe, quantity: 10 mg; atorvastatin calcium trihydrate, quantity: 43.4 mg (equivalent: atorvastatin, qty 40 mg) - tablet, multilayer - excipient ingredients: hyprolose; lactose monohydrate; croscarmellose sodium; silicon dioxide; magnesium stearate; microcrystalline cellulose; povidone; polysorbate 80; sodium lauryl sulfate; calcium carbonate; titanium dioxide; macrogol 8000; hypromellose; purified talc - prevention of cardiovascular disease atozet is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see clinical trials). primary hypercholesterolaemia atozet is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with atorvastatin or ezetimibe alone; - or already treated with atorvastatin and ezetimibe homozygous familial hypercholesterolaemia (hofh) atozet is indicated in patients with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -